NCT00025675 is a Phase 2 clinical trial of gefitinib in Brain and Central Nervous System Tumors, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Who is sponsoring NCT00025675?

NCT00025675 is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

What drugs are being tested in NCT00025675?

Interventions in NCT00025675: gefitinib.

What condition does NCT00025675 study?

NCT00025675 studies Brain and Central Nervous System Tumors.

Is NCT00025675 still recruiting?

NCT00025675 is currently completed. Last updated 26 June 2018.

Last reviewed 2018-06-26 · How we verify

NCT00025675

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gefitinib in Treating Patients With Recurrent or Progressive CNS Tumors

Completed Phase 2 Last updated 26 June 2018

What this trial tests

Phase 2 trial testing gefitinib in Brain and Central Nervous System Tumors in 105 participants. Completed in 2 January 2010.

Timeline

9 October 2001

Primary endpoint
5 July 2006

2 January 2010

Quick facts

Lead sponsor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	105
Start date	9 October 2001
Primary completion	5 July 2006
Estimated completion	2 January 2010
Sites	12 locations across United States

Drugs / interventions tested

gefitinib (gefitinib) — full drug profile →

Conditions studied

Brain and Central Nervous System Tumors — all drugs for Brain and Central Nervous System Tumors →

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — full company profile →

Who can join

Adults 18 to 120, any sex, with Brain and Central Nervous System Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Biological therapies such as gefitinib may interfere with the growth of tumor cells and slow the growth of CNS tumors. PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have recurrent or progressive CNS tumors.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance.
Wu W, Klockow JL, Zhang M, Lafortune F, et al · · 2021 · cited 532× · PMID 34302977 · DOI 10.1016/j.phrs.2021.105780
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma.
Li X, Wu C, Chen N, Gu H, et al · · 2016 · cited 406× · PMID 26967052 · DOI 10.18632/oncotarget.7961
Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review.
Kaley T, Barani I, Chamberlain M, McDermott M, et al · · 2014 · cited 198× · PMID 24500419 · DOI 10.1093/neuonc/not330
Targeting protein kinases in central nervous system disorders.
Chico LK, Van Eldik LJ, Watterson DM. · · 2009 · cited 197× · PMID 19876042 · DOI 10.1038/nrd2999
Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update.
Colardo M, Segatto M, Di Bartolomeo S. · · 2021 · cited 102× · PMID 34063168 · DOI 10.3390/ijms22094899
A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials.
Cruz Da Silva E, Mercier MC, Etienne-Selloum N, Dontenwill M, et al · · 2021 · cited 99× · PMID 33918704 · DOI 10.3390/cancers13081795
The Molecular and Microenvironmental Landscape of Glioblastomas: Implications for the Novel Treatment Choices.
Di Cintio F, Dal Bo M, Baboci L, De Mattia E, et al · · 2020 · cited 28× · PMID 33324155 · DOI 10.3389/fnins.2020.603647
Small Molecule Inhibitors in Adult High-Grade Glioma: From the Past to the Future.
Huang W, Hao Z, Mao F, Guo D. · · 2022 · cited 16× · PMID 35785151 · DOI 10.3389/fonc.2022.911876

Verify or expand the search:

Other trials of gefitinib

Trials testing the same drug.

NCT05834348 — A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in N · completed
NCT03486496 — Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation · Phase 2 · unknown
NCT03333343 — Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC · Phase 1 · active not recruiting
NCT03399669 — The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation · Phase 2 · unknown
NCT01466660 — LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positiv · Phase 2 · completed

Other recruiting trials for Brain and Central Nervous System Tumors

Currently open trials in the same condition.

NCT00978458 — Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma · Phase 3 · active not recruiting

Other Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins trials

Trials by the same sponsor.

NCT07424222 — Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) · Phase 1 · not yet recruiting
NCT06210854 — Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+ · Phase 2 · not yet recruiting
NCT07360119 — Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors · NA · not yet recruiting
NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00025675 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Last refreshed: 26 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00025675.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing